Lupin’s wholly owned subsidiary -- Nanomi B.V., the Netherlands (Nanomi) has entered into definitive agreements to acquire the minority shareholding from certain existing shareholders of Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary of Nanomi. This acquisition involves 11,794,497 shares, which accounts for 43.38% of the total outstanding paid up shares of MPPI. The transaction is expected to be completed by the end of May 2026, subject to certain closing conditions. 

The proposed acquisition will strengthen the company’s market standing in the Philippines market (through its wholly owned subsidiary Nanomi) and allow substantial integration of MPPI’s operations. It also allows strategic flexibility, enabling the company to unify emerging-market businesses and unlock long-term value.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.